Introduction {#s1}
============

Nigeria bears one of the world\'s highest burdens of malaria, accounting for a quarter of all cases in Africa [@pone.0110361-WHO1]. It is estimated that over half of Nigeria\'s population experiences at least one episode of malaria each year, accounting for approximately 20% of all hospital admission, 30% of outpatient visits, and 10% of hospital deaths [@pone.0110361-Okeke1]. This burden of disease strains the resources of the health system as spending on malaria treatment and prevention accounts for nearly 50% of all health expenditures in Nigeria [@pone.0110361-Onwujekwe1].

To effectively diagnose and treat malaria, the World Health Organization (WHO) currently recommends a confirmatory blood test for all suspected cases of malaria and prescription of artemisinin-based combination therapy (ACT) upon confirmation of malaria positivity [@pone.0110361-WHO2]. ACTs are currently the most effective antimalarial treatment and are becoming more widely available in Nigeria [@pone.0110361-AMFm1]. However, many health care providers in Nigeria continue to prescribe less-effective drugs, such as chloroquine (CQ) and sulfadoxine-pyrimethamine (SP), for uncomplicated cases of malaria [@pone.0110361-Mangham1]. Despite the increased availability of malaria rapid diagnostic tests (RDTs) to facilitate point-of-care diagnosis elsewhere in sub-Saharan Africa [@pone.0110361-Hamer1]--[@pone.0110361-Cohen1], RDTs are not yet widely available in Nigeria [@pone.0110361-Retail1] and presumptive diagnosis continues to be the most common method for determining a patient\'s malaria status [@pone.0110361-Uzochukwu1].

This study aims to better characterize the practice of presumptive treatment of malaria in Nigeria and determine where interventions for malaria treatment delivery should be targeted. Nearly 60% of Nigerians seek treatment for malaria at drug shop outlets in the private healthcare sector [@pone.0110361-National1]. Of these vendors, the minority is composed of licensed pharmacies, which are either owned or staffed by formally trained pharmacists, and which are mainly found in urban centers. The majority of vendors are informally trained, loosely regulated proprietary and patent medicine vendors (PPMVs), which are frequently the only source of drugs in rural areas [@pone.0110361-National1]--[@pone.0110361-Oladepo1]. While both types of vendors mainly operate as drug retailers, the quality of health services offered can vastly differ. PPMVs are legally permitted to only sell a number of medications over-the-counter, including antimalarial medications, but recent assessments show that they often do not stock ACTs, and have limited knowledge of malaria symptoms and recommended treatment guidelines [@pone.0110361-Goodman1]. In contrast, pharmacists are perceived to offer higher-quality malaria care services than PPMVs [@pone.0110361-DeLaCruz1], although little empirical evidence exists to corroborate these views.

When choosing the type of facility at which to seek care, patients may prioritize convenience, availability of familiar drugs, and affordability [@pone.0110361-DeLaCruz1]. While hospitals and clinics may provide higher quality care and testing, long wait and travel times often drive patients to accessible, nearby drug vendors. Similarly, there is little demand for confirmatory malaria microscopy testing, leading many people to bypass hospital/clinics or costly independent diagnostic laboratories [@pone.0110361-Ezeoke1].

Because private sector drug vendors are the source for such a large proportion of Nigeria\'s population seeking malaria care, it is important to understand the extent to which individuals seeking treatment for malaria are able to receive accurate diagnosis and treatment at pharmacies and PPMVs [@pone.0110361-Bastiaens1]. It is also important to understand what types of consumers may be at most risk for receiving poor quality services. Consequently, this study seeks to (1) describe and compare the profile of patients who seek treatment at PPMVs versus pharmacies, (2) document the types of drugs purchased for treating malaria, (3) assess which patients are purchasing recommended ACTs, and (4) estimate the extent of malaria over-treatment [@pone.0110361-Basu1]. Implications of findings for targeting appropriate diagnostic and treatment interventions are discussed.

Materials and Methods {#s2}
=====================

Ethical considerations {#s2a}
----------------------

The Nigerian Health Research Ethical Review Committee (NHREC Approval Number NHREC/01/01/2007-30/08/2012) and the University of California, San Francisco\'s Committee for Human Research approved all study protocols. Data collectors obtained written informed consent from study participants and shop proprietors where the customers were recruited. Written consent was obtained from shop proprietors via signature and customers via signature or fingerprint for non-literate customers. The consent procedure was approved by the Nigerian Health Research Ethical Review Committee and the University of California, San Francisco\'s Committee for Human Research. Funding sponsors for the study did have any role in the study design, execution, or publication.

Study area and sample selection {#s2b}
-------------------------------

The study was conducted in Oyo State, located in the Southwest geopolitical zone of Nigeria, comprised of about 4.5million people (predominantly of Yoruba descent) [@pone.0110361-Uzochukwu1]. Four local government areas (LGAs) were purposefully selected for the study to include urban, semi-urban, and rural areas: Ibadan South East (urban) andEgbeda (semi-urban) in and around the Ibadancity area, whileOgbomosho South and OgoOluwa were selected in and around the Ogbomosho town area (rural). All PPMV and pharmaceutical shops were first enumerated within the four selected LGAs and a total number of 236 PPMVs and 24 pharmaceutical shops were identified during the enumeration exercise. Interviewers used a questionnaire that captured the names, addresses, location (urban, seri-urban, rural), LGA, GPS coordinates, notable landmarks, and size of outlets ('small' for outlets with two shelves of medicines; 'medium' for outlets with three to four shelves of medicine; 'large' for outlets with more than five shelves).

From the complete list of shops, a total of fifty pharmacies and PPMVs were randomly selected, stratified by the size of medicinal stock (i.e. small, medium, and large). Selected shops were visited to inform shop owners of the study aims and obtain permission to recruit exiting customers into the study. Enrolled study sites were later modified to exclude 24 small PPMV drug retailers in Ibadan whose main business was not medicinal sales (thus participants were not able to be recruited) and replaced with randomly selected PPMV shops in Ibadan North East LGA. Using a standard script, 49 out of 50 selected private sector retailers (42shop in/around Ibadan, 7shops in/around Ogbomosho) agreedto havetheir shop used for participant recruitment and were enrolled into the study; only one pharmacy declined to participatefor reasons not stated. The final roster of recruitment sites consisted of 21 pharmacies and 23 PPMVs. All seven shops enrolled in Ogbomosho were PPMVs as the city did not have any pharmacies during site enumeration.

Two members of the survey team, one trained nurse and one researcher, were stationed at enrolled PPMVs and pharmacies on randomly selected days of the week (excluding Sunday) and approached customers as they exited the drug store to assess eligibility. The inclusion criteria were as follows: the participant must be a non-pregnant adult having purchased treatment for malaria for him-or herself and be willing to complete a 15-minute survey. Malaria "treatment" was defined to mean any drug purchased by the customer that s/he intended to take for their current episode of suspected malaria, which may include inappropriate drugs for malaria and not necessarily an antimalarial drug. While seeking consent, the participant was informed that if they qualified, they would be offered a RDT and would be compensated for their time with a small mobile phone credit of 200 Naira (∼US\$1.20) for participating in the interview.

Data collection {#s2c}
---------------

Two surveys were conducted, one at the time of enrollment and testing (i.e. baseline) and one after four days of the initial encounter via telephone call(i.e. follow-up). All data were collected concurrently. At baseline, the eligible participant was offered a RDT performed by a trained nurse at the beginning of the survey. While the RDT result was pending (about 15 minutes), a detailed survey was conducted designed to capture information on the background demographics and socioeconomic stats, symptoms experienced, and care-seeking actions taken for the current and past episodes of suspected malaria. Contact information was also collected during enrollment to facilitate later follow-up. At the end of the survey, the participant was provided with the result of his or her test.

Nurses were instructed to provide participants with standard advice according to their RDT results. If the participant tested positive for malaria, he/she was told that the positive result suggests the presence of malaria. Per ethical considerations to ensure that the participants testing positive had a quality-assured anti-malaria drug, a free course of ACTs was provided and participants were instructed to take it according to the recommended dosage protocol. If the test was negative, the participant was told that the negative result indicates the absence of malaria and that anti-malarial drugs they purchased were not needed. Regardless of the test result, all participants were referred to local clinics and hospitals where they could seek care if their condition was not malaria, or if their illness became worse. All participants were told to expect a short 5--10 minute follow up phone call in four days to check on the status of their illness and that they would be compensated with a small phone credit of 100 Naira (∼US\$0.60)for taking the call.

Four days after the baseline survey, a nurse called the participants and conducted a phone survey to obtain information on the state of their health and the drugs they had used. A total of 465 adults were enrolled in the baseline survey, but eight were excluded due to survey numbering errors, and 424 participated in the follow-up phone survey---a follow-up retention rate of 92.8%. No differences in individual characteristics between attritted and retained participants were detected; detailed sample attrition are described elsewhere [@pone.0110361-Modrek1].

Data Analysis {#s2d}
-------------

### Descriptive data analysis {#s2d1}

Descriptive analysis was used for the study to review the sample for basic socio demographic characteristics, reasons for choosing the drug shop, and drugs purchased and taken. Wealth distribution was assessed using standard principal components analysis (PCA) [@pone.0110361-Filmer1] in two ways. First, to compare the representativeness of the study sample to the overall state and national sample, weights associated with PCA component items generated from the 2010 Nigeria Malaria Indicator Survey (MIS) were applied to comparable asset indicators collected in the study sample to compute a wealth index that reflected the national wealth distribution. This index was then converted to quintile categorical indicators for comparing external sample representativeness. A second wealth index was created using only the study sample via the same PCA technique and converted to quintile indicators to obtain an even, within-sample distribution of wealth.

### Regression Analysis {#s2d2}

Two types of regression analyses were conducted. First, we estimated bivariate and multivariate logistic regressions to assess differences in the types of individuals that patron different types of drug shops---PPMVs versus pharmacies. The likelihood that a PPMV was chosen was predicted by the individual\'s age, sex, educational attainment, marital status, and wealth. In addition to basic socio demographics, employment status (i.e. full-time wage worker, part-time wage worker, self-employed, and unemployed) was included as shop owners indicated that customers tend to stop at drug shops on their way to and from work. Self-reported symptoms felt for the current illness episode, the number of days waited before seeking care, and where the recognition of the illness as malaria came from (i.e. myself/relative/friend, a hospital/clinic/diagnostic laboratory, or at a drug retailer) were also included because these factors may influence the choice of drug shop type based on perceived severity, need for drug administration, or recommendations by diagnosticians. Second, the likelihood of buying an ACT was predicted using logistic regression analysis. In addition to individual characteristics described above, the type of shop (i.e. PPMV vs. pharmacy) was included as a risk factor for receiving the recommended first-line malaria drug. In both analyses, only statistically significant explanatory variables at the 5% level in bivariate analysis were included in the multivariate model. To account for autocorrelation between individuals recruited at the same shop, standard errors were clustered at the shop level. Odds ratios are reported.

Findings {#s3}
========

Sample characteristics {#s3a}
----------------------

Of the 457participants who sought malaria treatment from the 49enrolled shops, 71.1% (n = 325) were recruited in Ibadan, 55.6% (n = 254) were under the age of 40 (median  = 37; range: 18--82), 50.8% were male (n = 232), and 68.1% (n = 311) were married. Only 22.5% (n = 103) had primary education or less; 39.8% (n = 182) completed secondary education and 37.6% (n = 172) had some tertiary level education. Among those interviewed, 31.3% (n = 143) were employed either on a full-time or part-time basis; 53.6% were self-employed (n = 245) and 15.1% were unemployed (n = 69). Participants reported feeling a variety of symptoms during their current episode of illness. Fever was most commonly reported (74.6%, n = 341), followed by body aches, chills, or convulsions (57.5%, n = 263), feeling weak, fatigued, or having little appetite (55.8%, n = 255). Nearly half of participants waited one day (18.7%, n = 79) or less (28.7%; n = 122) before seeking care; 34.3% (n = 146) waited three days or more. Nearly 92% (n = 423) of the participants reported that they had diagnosed the episode of malaria by themselves, a family member, or a friend. See [Table 1](#pone-0110361-t001){ref-type="table"} for a summary of the sample characteristics.

10.1371/journal.pone.0110361.t001

###### Customer demographic and socioeconomic variables (N = 457).

![](pone.0110361.t001){#pone-0110361-t001-1}

  Variable                                                                                            N     \%
  --------------------------------------------------------------------------- --------------------- ----- ------
  Site                                                                              Ogbomosho        132   28.9
                                                                                     Ibadan          325   71.1
  Age of respondents                                                                 18--29          127   27.8
                                                                                     30--39          127   27.8
                                                                                     40--49          100   21.9
                                                                                       50+           103   22.5
  Sex                                                                                 Male           232   50.8
                                                                                     Female          227   49.2
  Education                                                                       No education       130   28.4
                                                                                Primary education    13    2.8
                                                                               Secondary education   245   53.6
                                                                                Higher education     69    15.1
  Marital status                                                                   Not married       146   31.9
                                                                                     Married         311   68.1
  Employment status                                                            Employed full time    130   28.4
                                                                               Employed part time    13    2.8
                                                                                  Self-employed      245   53.6
                                                                                   Unemployed        69    15.1
  Wealth quintile[1](#nt101){ref-type="table-fn"}                                    Poorest         90    19.7
                                                                                     Second          92    20.1
                                                                                      Third          93    20.4
                                                                                     Fourth          90    19.7
                                                                                     Richest         92    20.1
  Symptoms reported                                                                                       
  Fever, headache, dizziness                                                           Yes           341   74.6
                                                                                       No            116   25.4
  Body aches, chills, convulsions                                                      Yes           263   57.5
                                                                                       No            194   42.5
  Weak, fatigue, no appetite                                                           Yes           255   55.8
                                                                                       No            202   44.2
  Bitter taste in the mouth                                                            Yes           62    13.6
                                                                                       No            395   86.4
  Congestion, shallow breathing                                                        Yes           58    12.7
                                                                                       No            399   87.3
  Vomiting, diarrhea                                                                   Yes           54    11.8
                                                                                       No            403   88.2
  Other: blisters, dark urine, yellow eyes                                             Yes           63    13.8
                                                                                       No            394   86.2
  Number of days waited before seeking care[2](#nt102){ref-type="table-fn"}          \<1 day         122   28.7
                                                                                      1 day          79    18.7
                                                                                     2 days          77    18.2
                                                                                    3--5 days        104   24.5
                                                                                 6 days or more      42    9.8
  Source of diagnosis                                                            Self-diagnosis      418   91.5
                                                                               Hospital/clinic/lab   20    4.4
                                                                                  Pharmacy/PPMV      19    4.2

Result of within-sample principle components analysis.

N = 424.

When comparing the wealth distribution between sampled individuals to that of the state and national populations captured by the 2010 MIS, those in the wealthiest quintile are disproportionately represented in the study sample. Based on the composite asset ownership measure, no individuals in the study sample were from the lowest two wealth quintiles of nation as seen in [Figure 1](#pone-0110361-g001){ref-type="fig"}. Although the population of Oyo State, and particularly in urban areas, is also comprised of households that are much wealthier than the nation as a whole, the study sample\'s wealth composition is even more concentrated among the wealthiest.

![Wealth distribution of enrolled participants versus state and national populations.\
When comparing the wealth distribution between sampled individuals to that of the state and national populations captured by the 2010 MIS, those in the wealthiest quintile are disproportionately represented in the study sample. Based on the composite asset ownership measure, no individuals in the study sample were from the lowest two wealth quintiles of nation. Although the population of Oyo State, and particularly in urban areas, is also comprised of households that are much wealthier than the nation as a whole, the study sample\'s wealth composition is even more concentrated among the wealthiest. Source: 2010 Nigeria Malaria Indicators Survey.](pone.0110361.g001){#pone-0110361-g001}

Types of medicines purchased for malaria treatment {#s3b}
--------------------------------------------------

[Table 2](#pone-0110361-t002){ref-type="table"} summarizes the types of drugs purchased at PPMVs and pharmacies for the current episode of suspected malaria among participants who agreed to have their drugs examined by the study nurse (n = 423). A significantly higher percentage of the patrons of pharmacies (57.4%, n = 132/230) purchased an ACT compared to only 28.5% (n = 55/193) of PPMV patrons (p\<0.01). Of non-ACT antimalarials purchased, significantly more customers at PPMVs (47.7%; n = 92/230) purchased SP than customers of pharmacies (28.7%, n = 66/193; p\<0.05). A higher percentage of PPMV customers also bought a non-malaria drug (70.1%, n = 136/194) compared to pharmacy customers (54.7%, n = 129/236). Significantly fewer analgesics (76.0%, n = 98/230), but more vitamins/supplements (85.3%, n = 110/230) and antibiotics (20.9%, n = 27/230) were purchased at pharmacies than at PPMVs (respectively: 92.6%, n = 126/193; 60.3%, n = 82/193; 5.9%, n = 8/193). More patrons of pharmacies bought only an antimalarial (45.3%, n = 107/230) compared to those at PPMVs (29.9%, n = 58/193). However, pharmacy customers paid significantly more for all of their drugs than those purchasing at PPMVs on average.

10.1371/journal.pone.0110361.t002

###### Drugs purchased to treat malaria.

![](pone.0110361.t002){#pone-0110361-t002-2}

                                                                Pharmacies   PPMVs    Total                          
  ------------------------------------------------------------ ------------ -------- ------- -------- ----- -------- ---------
  Type of anti-malarial drug[1](#nt103){ref-type="table-fn"}                                                         
  ACT                                                              132        57.4     55      28.5    187    44.2     0.003
  SP                                                                66        28.7     92      47.7    158    37.4     0.022
  CQ                                                                46        20.0     33      17.1    79     18.7     0.545
  Other                                                             21        9.1      16      8.3     37     8.7      0.830
  Purchased non-malaria drug                                                                                         
  Yes                                                              129        54.7     136     70.1    265    61.6     0.068
  No                                                               107        45.3     58      29.9    165    38.4   
  Type of non-malaria drugs                                                                                          
  Analgesic                                                         98        76.0     126     92.6    224    84.5     0.003
  Vitamin/supplement                                               110        85.3     82      60.3    192    72.5     0.007
  Antibiotic                                                        27        20.9      8      5.9     35     13.2     0.019
  Other                                                             16        12.4     11      8.1     27     10.2     0.251
  Purchase combinations                                                                                              
  Anti-malarial only                                               107        45.3     58      29.9    167    38.6     0.056
  Non-malaria drug only                                             6         1.3       1      0.3      7     0.8    
  Both anti-malarial and non-malaria drug                          123        26.2     135     34.9    259    30.1   
                                                                    n        median     n     median    n    median   P-value
  Total amount paid (median)                                       234        445      193     140     427    240      0.000

Pharmacies N = 230; PPMVs N = 193; Total N = 423. Not all participants purchased an anti-malarial drug.

Correlates of seeking care at a PPMV versus a pharmacy {#s3c}
------------------------------------------------------

Results of logistics regressions predicting the likelihood of going to a PPMV versus a pharmacy for malaria treatment are summarized in [Table 3](#pone-0110361-t003){ref-type="table"}. In bivariate analyses, customers going to different shop types were significantly different in terms of their age, educational attainment, employment status, and wealth. Significant differences were also registered for a number of symptoms (i.e. fever, headache, or dizziness; feeling weak, fatigues, or no appetite; having congestion or shallow breathing; and other symptoms including blusters, dark urine, and yellow eyes), days waited before seeking care, and the source of diagnosis. In multivariate analyses, older individuals are about half as likely to patron a PPMV (age 30--39: OR = 0.416, 95% CI: 0.230--0.752; age 50+: OR = 0.461, 95% CI: 0.229--0.929) than those under age 30. A strong wealth gradient emerges with the individuals in progressively richer wealth quintiles increasingly less likely to go to a PPMV compared to those in the poorest quintile. Those reporting other types of symptoms (i.e. blisters, dark urine, yellow eyes) were more than three times as likely to go to a PPMV (OR = 3.138, 95% CI: 1.381--7.128) while those reporting fever, headache, or dizziness (OR = 2.589, 95% CI: 1.501--4.465) and weakness, fatigue, and lack of appetite (OR = 1.951, 95% CI: 1.043--3.649) were about twice as likely to go to a PPMV. When individuals waited one day before seeking care, they were twice as likely to go to a PPMV (OR = 2.070, 95% CI: 1.256--3.411) compared to those who sought treatment the same day; the likelihood of PPMV patronage progressively declined as the number of days waited increased, but these were not statistically significant. Diagnosis coming from a hospital, clinic, or laboratory was associated with a large and significantly lower likelihood of going to a PPMV (OR = 0.022, 95% CI: 0.137--1.311). Education and employment status were no longer statistically significant after adjusting for all confounders.

10.1371/journal.pone.0110361.t003

###### Logistic regression of the likelihood of buying drugs from a PPMV (versus a pharmacy).

![](pone.0110361.t003){#pone-0110361-t003-3}

                                                                                                                  Pharmacy   PPMV         Bivariate   Multivariate                                                                                                                                   
  --------------------------------------------------------------------------- ---------------------------------- ---------- ------ ----- ----------- -------------- --------------------------------------------- -------------- ------- -------------------------------------------- -------------- --------
  Age of respondents                                                                  18--29 (reference)             52      21.2   74      34.9         0.005                          1.000                                                               1.000                                    
                                                                                            30--39                   78      31.8   49      23.1                     0.441[\*\*\*](#nt107){ref-type="table-fn"}    0.275--0.709   0.001   0.416[\*\*\*](#nt107){ref-type="table-fn"}   0.230--0.752   0.004
                                                                                            40--49                   56      22.9   44      20.8                                        0.552                      0.268--1.139   0.108                     0.564                      0.255--1.249   0.158
                                                                                             50+                     59      24.1   45      21.2                      0.524[\*\*](#nt108){ref-type="table-fn"}     0.292--0.939   0.030    0.461[\*\*](#nt108){ref-type="table-fn"}    0.229--0.929   0.030
  Sex                                                                                        Male                   125      51.0   106     50.0         0.893                          0.969                      0.615--1.528   0.893                                                              
                                                                                      Female (reference)            120      49.0   106     50.0                                        1.000                                                                                                        
  Education                                                                        No education (reference)          10      4.1    28      13.2         0.012                          1.000                                                               1.000                                    
                                                                                      Primary education              24      9.8    42      19.8                                        0.610                      0.247--1.504   0.283                     0.984                      0.319--3.033   0.977
                                                                                     Secondary education            102      41.6   79      37.3                      0.277[\*\*](#nt108){ref-type="table-fn"}     0.102--0.749   0.012                     0.470                      0.157--1.407   0.177
                                                                                       Higher education             109      44.5   63      29.7                     0.206[\*\*\*](#nt107){ref-type="table-fn"}    0.064--0.667   0.008                     0.607                      0.136--2.712   0.514
  Marital status                                                                   Not married (reference)           66      26.9   80      37.7         0.089                          1.000                                                                                                        
                                                                                           Married                  179      73.1   132     62.3                       0.616[\*](#nt109){ref-type="table-fn"}      0.352--1.077   0.089                                                              
  Employment status                                                             Employed full time (reference)       83      33.9   47      22.3         0.012                          1.000                                                               1.000                                    
                                                                                      Employed part time             8       3.3     5       2.4                                        1.104                      0.240--5.078   0.899                     0.463                      0.085--2.520   0.373
                                                                                        Self-employed               111      45.3   134     63.0                     2.116[\*\*\*](#nt107){ref-type="table-fn"}    1.205--3.717   0.009                     1.337                      0.627--2.849   0.452
                                                                                          Unemployed                 43      17.6   26      12.3                                        1.068                      0.581--1.962   0.833                     0.761                      0.299--1.940   0.567
  Wealth quintile                                                                    Poorest (reference)             21      8.6    68      32.1         0.000                          1.000                                                               1.000                                    
                                                                                            Second                   38      15.5   54      25.5                     0.439[\*\*\*](#nt107){ref-type="table-fn"}    0.235--0.819   0.010    0.430[\*\*](#nt108){ref-type="table-fn"}    0.205--0.900   0.025
                                                                                            Third                    53      21.6   40      18.9                     0.233[\*\*\*](#nt107){ref-type="table-fn"}    0.126--0.431   0.000   0.205[\*\*\*](#nt107){ref-type="table-fn"}   0.087--0.487   0.000
                                                                                            Fourth                   59      24.1   32      15.1                     0.162[\*\*\*](#nt107){ref-type="table-fn"}    0.072--0.368   0.000   0.152[\*\*\*](#nt107){ref-type="table-fn"}   0.056--0.413   0.000
                                                                                           Richest                   74      30.2   18       8.5                     0.0751[\*\*\*](#nt107){ref-type="table-fn"}   0.023--0.249   0.000   0.075[\*\*\*](#nt107){ref-type="table-fn"}   0.018--0.318   0.000
  Symptoms reported                                                                                                                                                                                                                                                                                  
  Fever, headache, dizziness                                                                 Yes                    168      68.6   172     81.1         0.001       2.021[\*\*\*](#nt107){ref-type="table-fn"}    1.317--3.101   0.001   2.589[\*\*\*](#nt107){ref-type="table-fn"}   1.501--4.465   0.000
                                                                                        No (reference)               77      31.4   40      18.9                                        1.000                                                               1.000                                    
  Body aches, chills, convulsions                                                            Yes                    130      53.1   133     62.7         0.096         1.508[\*](#nt109){ref-type="table-fn"}      0.929--2.448   0.096                                                              
                                                                                        No (reference)              115      46.9   79      37.3                                        1.000                                                                                                        
  Weak, fatigue, no appetite                                                                 Yes                    120      49.0   134     63.2         0.011        1.813[\*\*](#nt108){ref-type="table-fn"}     1.144--2.872   0.011    1.951[\*\*](#nt108){ref-type="table-fn"}    1.043--3.649   0.036
                                                                                        No (reference)              125      51.0   78      36.8                                        1.000                                                               1.000                                    
  Bitter taste in the mouth                                                                  Yes                     29      11.8   33      15.6         0.241                          1.381                      0.806--2.367   0.240                                                              
                                                                                        No (reference)              216      88.2   179     84.4                                        1.000                                                                                                        
  Congestion, shallow breathing                                                              Yes                     38      15.5   20       9.4         0.016        0.570[\*\*](#nt108){ref-type="table-fn"}     0.361--0.902   0.016     0.619[\*](#nt109){ref-type="table-fn"}     0.372--1.030   0.065
                                                                                        No (reference)              207      84.5   192     90.6                                        1.000                                                               1.000                                    
  Vomiting, diarrhea                                                                         Yes                     30      12.2   24      11.3         0.752                          0.920                      0.548--1.545   0.752                                                              
                                                                                        No (reference)              215      87.8   188     88.7                                        1.000                                                                                                        
  Other: blisters, dark urine, yellow eyes                                                   Yes                     15      6.1    48      22.6         0.000       4.515[\*\*\*](#nt107){ref-type="table-fn"}    2.345--8.696   0.000   3.138[\*\*\*](#nt107){ref-type="table-fn"}   1.381--7.128   0.0063
                                                                                        No (reference)              230      93.9   164     77.4                                        1.000                                                               1.000                                    
  Number of days waited before seeking care[2](#nt105){ref-type="table-fn"}          \<1 day (reference)             56      25.9   65      31.7         0.016                          1.000                                                               1.000                                    
                                                                                            1 day                    30      13.9   49      23.9                                        1.378                      0.854--2.225   0.189   2.070[\*\*\*](#nt107){ref-type="table-fn"}   1.256--3.411   0.004
                                                                                            2 days                   37      17.1   40      19.5                                        0.931                      0.510--1.700   0.817                     1.624                      0.890--2.962   0.114
                                                                                          3--5 days                  66      30.6   37      18.0                       0.483[\*](#nt109){ref-type="table-fn"}      0.220--1.058   0.069                     0.659                      0.289--1.504   0.322
                                                                                        6 days or more               27      12.5   14       6.8                       0.447[\*](#nt109){ref-type="table-fn"}      0.181--1.100   0.080                     0.431                      0.137--1.355   0.150
  Source of diagnosis                                                          Myself/family/friend (reference)     213      86.9   205     96.7         0.011                          1.000                                                               1.000                                    
                                                                                     Hospital/clinic/lab             19      7.8     1       0.5                     0.055[\*\*\*](#nt107){ref-type="table-fn"}    0.008--0.393   0.004    0.022[\*\*](#nt108){ref-type="table-fn"}    0.001--0.412   0.011
                                                                                        Pharmacy/PPMV                13      5.3     6       2.8                                        0.482                      0.149--1.557   0.222                     0.424                      0.137--1.311   0.136
  Observations                                                                                                                                            457                                                                      420                                                               

Odds ratios reported.

Pharmacy (n = 212), PPMV (n = 205), Total (n = 417).

Standard errors are clustered at the shop level;

\*\*\*p\<0.01,

\*\*p\<0.05,

\*p\<0.1.

When asked for reasons why they chose the particular drug shop, most respondents stated reasons of habit and convenience (see [Figure 2](#pone-0110361-g002){ref-type="fig"}). A significantly higher percentage of participants at PPMVs said that the shop was convenient and had the drugs that s/he needed. In similar percentages, both types of outlets were cited for their prices.
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When asked for reasons why they chose the particular drug shop, most respondents stated reasons of habit and convenience (see [Figure 2](#pone-0110361-g002){ref-type="fig"}). A significantly higher percentage of participants at PPMVs said that the shop was convenient and had the drugs that s/he needed. In similar percentages, both types of outlets were cited for their prices. Note: \*\*\* p\<0.01, \*\* p\<0.05, \* p\<0.1.](pone.0110361.g002){#pone-0110361-g002}

Predictors of purchasing an ACT {#s3d}
-------------------------------

The logistic regression results predicting the likelihood of purchasing an ACT over other types of antimalarial drugs are listed in [Table 4](#pone-0110361-t004){ref-type="table"}. In bivariate analyses, shop type, wealth, and the source of diagnoses were the only factors that were significantly associated with the likelihood of buying an ACT. In adjusted regressions, customers who went to PPMVs were significantly less likely to buy an ACT (OR = 0.371, 95% CI: 0.168-0.821). While having a diagnosis from a hospital, clinic, or laboratory was associated with increased likelihood of ACT purchase, this was only marginally significant at the 10% level. Differences in wealth were no longer significant in the multivariate specification, although a gradient was still observed.

10.1371/journal.pone.0110361.t004

###### Logistic regression of the likelihood of buying an ACT (versus other anti-malarial drugs).

![](pone.0110361.t004){#pone-0110361-t004-4}

                                                                                                                  ACT   Other anti-malarial         Bivariate   Multivariate                                                                                                                                 
  --------------------------------------------------------------------------- ---------------------------------- ----- --------------------- ----- ----------- -------------- -------------------------------------------- -------------- -------- ------------------------------------------ -------------- -------
  Type of shop^1^                                                                            PPMV                 136          58.4           136     29.3         0.002       0.296[\*\*\*](#nt113){ref-type="table-fn"}   0.135--0.650   0.002    0.371[\*\*](#nt114){ref-type="table-fn"}   0.168--0.821   0.015
                                                                                           Pharmacy               97           41.6           97      70.7                                       1.000                                                               1.000                                   
  Age of respondents                                                                  18--29 (reference)          70           30.0           70      22.3         0.541                         1.000                                                                                                       
                                                                                            30--39                64           27.5           64      29.3                                       1.441                      0.800--2.595   0.224                                                             
                                                                                            40--49                52           22.3           52      23.9                                       1.445                      0.775--2.694   0.247                                                             
                                                                                             50+                  47           20.2           47      24.5                                       1.635                      0.767--3.485   0.203                                                             
  Sex                                                                                        Male                 125          53.6           125     48.4         0.398                         0.809                      0.496--1.322   0.398                                                             
                                                                                      Female (reference)          108          46.4           108     51.6                                       1.000                                                                                                       
  Education                                                                        No education (reference)       18            7.7           18       6.5         0.182                         1.000                                                                                                       
                                                                                      Primary education           36           15.5           36       9.8                                       0.750                      0.300--1.873   0.538                                                             
                                                                                     Secondary education          96           41.2           96      39.1                                       1.125                      0.513--2.466   0.769                                                             
                                                                                       Higher education           83           35.6           83      44.6                                       1.482                      0.647--3.395   0.352                                                             
  Marital status                                                                   Not married (reference)        76           32.6           76      29.9         0.654                         1.000                                                                                                       
                                                                                           Married                157          67.4           157     70.1                                       1.135                      0.652--1.978   0.654                                                             
  Employment status                                                             Employed full time (reference)    59           25.3           59      34.2         0.105                         1.000                                                                                                       
                                                                                      Employed part time           6            2.6            6       2.7                                       0.780                      0.174--3.499   0.746                                                             
                                                                                        Self-employed             136          58.4           136     46.2                      0.585[\*\*](#nt114){ref-type="table-fn"}    0.368--0.930   0.023                                                             
                                                                                          Unemployed              32           13.7           32      16.8                                       0.907                      0.541--1.522   0.712                                                             
  Wealth quintile                                                                    Poorest (reference)          50           21.5           50      14.7         0.008                         1.000                                                               1.000                                   
                                                                                            Second                59           25.3           59      14.1                                       0.816                      0.454--1.466   0.497                     0.652                     0.357--1.192   0.165
                                                                                            Third                 48           20.6           48      17.4                                       1.235                      0.610--2.500   0.558                     0.875                     0.412--1.861   0.730
                                                                                            Fourth                44           18.9           44      23.9                                       1.852                      0.870--3.943   0.110                     1.234                     0.615--2.477   0.554
                                                                                           Richest                32           13.7           32      29.9                     3.183[\*\*\*](#nt113){ref-type="table-fn"}   1.499--6.758   0.003                     1.931                     0.880--4.236   0.101
  Symptoms reported                                                                                                                                                                                                                                                                                          
  Fever, headache, dizziness                                                                 Yes                  171          73.4           171     73.4         0.996                         0.999                      0.635--1.571   0.996                                                             
                                                                                        No (reference)            62           26.6           62      26.6                                       1.000                                                                                                       
  Body aches, chills, convulsions                                                            Yes                  136          58.4           136     57.1         0.818                         0.948                      0.601--1.494   0.818                                                             
                                                                                        No (reference)            97           41.6           97      42.9                                       1.000                                                                                                       
  Weak, fatigue, no appetite                                                                 Yes                  138          59.2           138     54.3         0.387                         0.820                      0.522--1.287   0.387                                                             
                                                                                        No (reference)            95           40.8           95      45.7                                       1.000                                                                                                       
  Bitter taste in the mouth                                                                  Yes                  31           13.3           31      14.7         0.654                         1.121                      0.681--1.844   0.654                                                             
                                                                                        No (reference)            202          86.7           202     85.3                                       1.000                                                                                                       
  Congestion, shallow breathing                                                              Yes                  24           10.3           24      16.3         0.110                         1.696                      0.887--3.244   0.110                                                             
                                                                                        No (reference)            209          89.7           209     83.7                                       1.000                                                                                                       
  Vomiting, diarrhea                                                                         Yes                  26           11.2           26      10.9         0.916                         0.971                      0.561--1.679   0.916                                                             
                                                                                        No (reference)            207          88.8           207     89.1                                       1.000                                                                                                       
  Other: blisters, dark urine, yellow eyes                                                   Yes                  33           14.2           33      11.4         0.448                         0.781                      0.412--1.480   0.448                                                             
                                                                                        No (reference)            200          85.8           200     88.6                                       1.000                                                                                                       
  Number of days waited before seeking care[1](#nt110){ref-type="table-fn"}          \<1 day (reference)          68           30.8           68      24.8         0.140                         1.000                                                                                                       
                                                                                            1 day                 46           20.8           46      15.5                                       0.924                      0.455--1.875   0.827                                                             
                                                                                            2 days                42           19.0           42      18.6                                       1.214                      0.691--2.135   0.500                                                             
                                                                                          3--5 days               45           20.4           45      29.2                      1.776[\*\*](#nt114){ref-type="table-fn"}    1.038--3.039   0.0362                                                            
                                                                                        6 days or more            20            9.0           20      11.8                                       1.615                      0.798--3.269   0.183                                                             
  Source of diagnosis                                                          Myself/family/friend (reference)   219          94.0           219     89.1         0.019                         1.000                                                               1.000                                   
                                                                                     Hospital/clinic/lab           4            1.7            4       7.1                      4.340[\*\*](#nt114){ref-type="table-fn"}    1.323--14.24   0.0155    3.124[\*](#nt115){ref-type="table-fn"}    0.987--9.894   0.053
                                                                                        Pharmacy/PPMV             10            4.3           10       3.8                                       0.935                      0.345--2.530   0.894                     0.758                     0.301--1.909   0.557
  Observations                                                                                                                                                      417                                                                     417                                                              

Odds ratios reported.

Pharmacy (n = 221), PPMV (n = 161), Total (n = 382).

Standard errors are clustered at the shop level;

\*\*\*p\<0.01,

\*\*p\<0.05,

\*p\<0.1.

RDT results and self-reported drug administration {#s3e}
-------------------------------------------------

Of the 457 enrolled participants, 3.9% (n = 18) were RDT-positive as seen in [Table 5](#pone-0110361-t005){ref-type="table"}. During the phone follow-up survey, 97.9% (n = 415/424) of those reached reported that they felt better than the day they were enrolled into the study and 5.9% (n = 25/422) had sought additional care. For those who were RDT-positive (and for whom drug information is available), 68.8% (n = 11/16) reported taking an ACT; none took a non-ACT anti-malarial and all took some type of non-anti-malarial drug that they had also purchased (n = 12). Among RDT-negative participants, 28.9% still used some form of anti-malarial medication: 9.7% (n = 39/402) took an ACT and 19.2% (n = 77/402) took a non-ACT anti-malarial. For those who also purchased a non-anti-malarial, 76.5% (n = 189/247) took these drugs. When asked which places could be trusted to provide RDTs, 77.4% (n = 328/425) indicated hospitals or clinics and 17.5% (n = 74) named a diagnostic laboratory; only 4.2% stated pharmacies, 1.2% (n = 5) named PPMVs, and 3.5% (n = 15) indicated a family or friend could be trusted.

10.1371/journal.pone.0110361.t005

###### RDT result and self-reported drug administration.

![](pone.0110361.t005){#pone-0110361-t005-5}

                                                         n     N     \%
  ----------------------------------------- ---------- ----- ----- ------
  RDT result                                 Positive   18    457   3.9
                                             Negative   439   457   96.1
  Generally feeling better since baseline      Yes      415   424   97.9
                                                No       9    424   2.1
  Drugs taken                                                      
  RDT-positive                                                     
  ACT                                          Yes      11    16    68.8
                                                No       5    16    31.3
  Non-ACT anti-malarial                        Yes       0    16     0
                                                No       0    16     0
  Non-anti-malarial                            Yes      12    12    100
                                                No       0    12     0
  RDT-negative                                                     
  ACT                                          Yes      39    402   9.7
                                                No      363   402   90.3
  Non-ACT anti-malarial                        Yes      77    402   19.2
                                                No      325   402   80.8
  Non-anti-malarial                            Yes      189   247   76.5
                                                No      58    247   23.5
  Sought additional care                       Yes      25    422   5.9
                                                No      397   422   94.1
  Places trusted to provide RDTs                                   
  Hospital/clinic                              Yes      328   424   77.4
                                                No      96    424   22.6
  Diagnostic lab                               Yes      74    424   17.5
                                                No      350   424   82.5
  Pharmacy                                     Yes      18    424   4.2
                                                No      406   424   95.8
  PPMV                                         Yes       5    424   1.2
                                                No      419   424   98.8
  Community health worker                      Yes      23    424   5.4
                                                No      401   424   94.6
  Traditional healer                           Yes       4    424   0.9
                                                No      420   424   99.1
  Family/friend                                Yes      15    424   3.5
                                                No      409   424   96.5
  Felt well at follow up and RDT positive                          
  Took ACTs                                    Yes       9    16    56.3
                                                No       7    16    43.7
  Took non- ACT anti-malarial                  Yes       7    16    43.7
                                                No       9    16    56.7
  Non- antimalarial                            Yes       0    16     0
                                                No      16    16    100
  Felt well at follow up and RDT negative                          
  Took ACTs                                    Yes      206   389   53.0
                                                No      183   389   47.0
  Took non- ACT anti-malarial                  Yes      181   389   46.5
                                                No      208   389   53.5
  Non- antimalarial                            Yes       2    389   0.5
                                                No      387   389   99.5

Discussion {#s4}
==========

Like elsewhere in sub-Saharan Africa [@pone.0110361-Goodman1], [@pone.0110361-Nshakira1]--[@pone.0110361-Wafula1], medicine retailers in Nigeria are an important source of treatment for uncomplicated malaria even though the quality of care and knowledge among these providers is poorer compared to other types of health professionals. This study sought to better characterize the practice of presumptive treatment at drug outlets in Nigeria. Recruited as they exited drug shops, nearly all study participants reported that they had self-diagnosed their condition and chose to patron the particular shop because it was either their usual place to buy drugs or was convenient. Individuals who went to PPMVs were typically younger, poorer, waited fewer days before seeking care, and had not gone to a hospital/clinic for diagnosis. These results suggest that relatively poorer populations, and potentially less-educated, are disproportionately serviced by PPMVs, potentially motivated by a variety of factors, including proximity and accessibility [@pone.0110361-Snow1], [@pone.0110361-VanDerGeest1] and cost [@pone.0110361-Amin1], [@pone.0110361-Brieger1].

In this study, even though patrons of PPMVs spent less on their drug purchases on average, they were also more likely to purchase sub-standard, non-ACT anti-malarials. Going to a PPMV was the largest risk factor for not buying an ACT, indicating that PPMVs continue to sell non-recommended drugs for malaria. Studies show that receiving ACTs is highly associated with consumer demand [@pone.0110361-Mangham1], and that PPMVs in particular tend to sell what customers demand and avoid referring patients for confirmatory blood tests because they fear losing customers due to added inconvenience or cost [@pone.0110361-DeLaCruz1]. Thus, consumer preferences for presumptive treatment and non-recommended drugs may drive individuals to patron PPMVs rather than pharmacies, even both types of outlets are generally perceived to provider lower quality services than hospitals or clinics [@pone.0110361-Onwujekwe2]. Profit motives may further constrain proper dispensing behavior due to strong consumer demand for substandard drugs [@pone.0110361-Wafula1].

In addition to fever, many participants attributed a wide variety of symptoms to malaria, and those going to PPMVs were especially likely to name symptoms unrelated to malaria. Further, only 3.9% of sick adults seeking care for malaria were found to be positive for malaria using an RDT. This corroborates qualitative evidence that malaria is identified as the illness for a large swath of conditions in Nigeria [@pone.0110361-DeLaCruz1], and that malaria is over-diagnosed and over-treated, similar to other urban areas of Nigeria [@pone.0110361-Oyibo1] and elsewhere in sub-Saharan malaria-endemic countries [@pone.0110361-Crump1]--[@pone.0110361-Mangham2]. There is also an entrenched perception that malaria is rampant and many people have been regaled with the need to treat malaria promptly by public health messages in the past aimed at increasing awareness. This highlights the importance of malaria behavior change messages that inform people that not all fever cases can be attributed to malaria and the need for individuals to seek out malaria diagnosis.

Although the study did not have a comparison control group, it is assumed that most sick individuals who purchased malaria drugs in this study were intending to take their purchased drugs to presumptively treatment him/herself. Over 44% of participants bought ACTs and the median amount spent on purchasing anti-malarial drugs was 240 Naira (∼US\$1.50). This level of overtreatment suggests that large quantities of ACTs may be wasted if reliable testing is not first carried out. It is therefore imperative to train all health workers as well as the populace on malaria symptoms and the need for a diagnostic test has become vital in health communications and education. Since PPMVs and pharmacies serve the majority of the population seeking treatment for malaria, standard diagnostic testing prior to treatment should be considered as part of a concerted strategy for malaria control. Some countries, including Tanzania, Senegal, and Zambia have successfully implemented RDTs in the public health sector and provider acceptability has improved over time, resulting in sizable cost-savings [@pone.0110361-Hamer1]--[@pone.0110361-Yukich1]. Further, this is the first study to assess patient adherence to test results (rather than provider prescription behavior) showing that simply providing diagnostic information to sick individuals can result in high rates of appropriate treatment behavior [@pone.0110361-Modrek1].

In addition, this also underscores the need to provide alternative means of management of non-malaria febrile illness. There is currently not a good understanding of the etiology of non-malaria febrile illnesses and only a handful of studies have documented the variety of causes of pediatric illnesses in select countries [@pone.0110361-Crump1], [@pone.0110361-Acestor1]. Such information is vital for developing more comprehensive treatment guidelines for childhood illnesses that are country-relevant and should be the focus of future studies.

Limitations of the study {#s4a}
------------------------

Populations in Southwest Nigeria are likely to be from higher socioeconomic status than populations in other areas of the country and consequently likely to be healthier overall [@pone.0110361-National1]. A sample of adults as carried out in the study may not necessarily be representative of children under five who are yet to develop immunity to malaria. Further studies will be needed to look at the incidence of malaria in this group as well as in other parts of Nigeria to determine if this picture is consistent nationwide. Characteristics of the shop and its workers may also be important determinants of shop patronage and buying drugs which the current study was not able to capture, but which future studies will aim to include in the assessment of care-seeking behavior for malaria.

The study could not look at counterfeit or substandard drugs purchased at the medicine shops. However, quality-assured ACTs were given free of charge in order to address the risk of participants taking substandard drugs. Although shop workers did not participate in the recruitment or screening of customer participants, they may have altered their sales or prescriptive behavior in ways that we cannot account for.
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